Compare FLEX & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLEX | TEVA |
|---|---|---|
| Founded | 1990 | 1901 |
| Country | United States | Israel |
| Employees | 147979 | 32842 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 33.5B |
| IPO Year | 1997 | N/A |
| Metric | FLEX | TEVA |
|---|---|---|
| Price | $95.09 | $35.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $66.89 | $38.63 |
| AVG Volume (30 Days) | 3.3M | ★ 5.5M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $28,679,925,000.00 | N/A |
| Revenue This Year | $8.14 | N/A |
| Revenue Next Year | $6.28 | $2.97 |
| P/E Ratio | $55.34 | ★ $28.19 |
| Revenue Growth | ★ 18.95 | N/A |
| 52 Week Low | $34.94 | $14.99 |
| 52 Week High | $93.53 | $37.35 |
| Indicator | FLEX | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 76.55 | 71.92 |
| Support Level | $60.15 | $30.53 |
| Resistance Level | N/A | $37.35 |
| Average True Range (ATR) | 3.14 | 0.96 |
| MACD | 0.45 | 0.49 |
| Stochastic Oscillator | 98.39 | 95.24 |
Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.